SCHEMBL20973143

SCHEMBL20973143

OC[C@H]1O[C@@H](n2c3ncnc(-c4cc5ccccc5o4)c3c3ccsc32)[C@H](O)[C@@H]1O

nearest known ligand 0.71

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 14/20 0.71
▸ GAPDH P04406 1/20 0.43
▸ CCNA2 P20248 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ CCNA1 P78396 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20973132 0.83 ADK (0.69) ADKGAPDHCCNA2CDK2CCNA1
SCHEMBL21368953 0.82 ADK (0.71) ADK
SCHEMBL20973142 0.82 ADK (0.48) ADKGAPDHCCNA2CDK2CCNA1
SCHEMBL19837982 0.80 ADK (1.00) ADKGAPDHCCNA2CDK2CCNA1
SCHEMBL21368887 0.80 ADK (0.73) ADKGAPDH
SCHEMBL19837993 0.79 ADK (1.00) ADKGAPDH
SCHEMBL21351705 0.79 ADK (1.00) ADKGAPDH
SCHEMBL20973154 0.78 ADK (0.61) ADK
SCHEMBL20973215 0.78 GAPDH (0.48) ADKGAPDHCCNA2CDK2CCNA1
SCHEMBL20973489 0.78 CDK5 (0.59) ADKGAPDHCCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190144487-A1 SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US claimed
US-10414788-B2 Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-09-17 — — US disclosed
US-10414788-B2 Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-09-17 — — US disclosed
US-20190144487-A1 SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US disclosed
US-20190144487-A1 SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144487-A1 SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE TYMP, DPYD, TK2 ADK 1290/4885GAPDH 543/4885CCNA2 338/4885
US-10414788-B2 Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use TYMP, DPYD, TK2 ADK 1290/4885GAPDH 543/4885CCNA2 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback